Moomoo AIのまとめ
On June 10, 2024, Vivos Therapeutics, Inc., a medical technology company specializing in treatments for sleep-related breathing disorders, entered into a securities purchase agreement with V-CO Investors LLC, an affiliate of New Seneca Partners Inc. The agreement involved a private placement offering where Vivos sold shares and warrants to V-CO, resulting in gross proceeds of $7.5 million for Vivos. The funds are intended for general corporate purposes and working capital. Concurrently, Vivos' subsidiary VSI Providers, PLLC, and Rebis Health Holdings, LLC entered into a strategic alliance agreement for joint marketing and distribution, targeting sleep apnea treatment solutions. Additionally, a management services agreement was signed between Vivos, Airway Integrated Management Company, LLC, and V-CO, where V-CO will provide management and advisory services related to the strategic alliance. The private placement and strategic agreements were announced in a press release on June 12, 2024, and aim to enhance Vivos' revenue streams and potential profit through collaborative efforts in marketing and distribution.
On June 10, 2024, Vivos Therapeutics, Inc., a medical technology company specializing in treatments for sleep-related breathing disorders, entered into a securities purchase agreement with V-CO Investors LLC, an affiliate of New Seneca Partners Inc. The agreement involved a private placement offering where Vivos sold shares and warrants to V-CO, resulting in gross proceeds of $7.5 million for Vivos. The funds are intended for general corporate purposes and working capital. Concurrently, Vivos' subsidiary VSI Providers, PLLC, and Rebis Health Holdings, LLC entered into a strategic alliance agreement for joint marketing and distribution, targeting sleep apnea treatment solutions. Additionally, a management services agreement was signed between Vivos, Airway Integrated Management Company, LLC, and V-CO, where V-CO will provide management and advisory services related to the strategic alliance. The private placement and strategic agreements were announced in a press release on June 12, 2024, and aim to enhance Vivos' revenue streams and potential profit through collaborative efforts in marketing and distribution.
2024年6月10日、睡眠関連の呼吸障害治療に特化した医療関連テクノロジー企業Vivos Therapeutics, Inc.は、New Seneca Partners Inc.の関連会社であるV-CO Investors LLCと有価証券購入契約を締結しました。契約は、VivosがV-COに株式とwarrantsを売却する非公募発行のオファリングを含み、Vivosは7.5百万ドルの総収益を得ました。資金は、一般的な企業目的と運転資金に充てられます。同時に、Vivosの子会社であるVSI Providers, PLLCとRebis Health Holdings, LLCは、睡眠時無呼吸症の治...すべて展開
2024年6月10日、睡眠関連の呼吸障害治療に特化した医療関連テクノロジー企業Vivos Therapeutics, Inc.は、New Seneca Partners Inc.の関連会社であるV-CO Investors LLCと有価証券購入契約を締結しました。契約は、VivosがV-COに株式とwarrantsを売却する非公募発行のオファリングを含み、Vivosは7.5百万ドルの総収益を得ました。資金は、一般的な企業目的と運転資金に充てられます。同時に、Vivosの子会社であるVSI Providers, PLLCとRebis Health Holdings, LLCは、睡眠時無呼吸症の治療ソリューションをターゲットにした共同マーケティングおよび流通の戦略提携契約を締結しました。さらに、Vivos、Airway Integrated Management Company, LLC、およびV-COの間でマネジメントサービス契約が締結され、V-COは戦略提携に関連するマネジメントおよびアドバイザリーサービスを提供します。この非公募発行および戦略提携に関する契約は2024年6月12日にプレスリリースで発表され、マーケティングおよび流通における協力により、Vivosの売上高および潜在的な利益を向上させることを目的としています。
役に立った
役に立たない